Journal article

Impulsive-Compulsive Spectrum Behaviors in Pathologically Confirmed Progressive Supranuclear Palsy

Sean S O'Sullivan, Atbin Djamshidian, Zeshan Ahmed, Andrew H Evans, Andrew D Lawrence, Janice L Holton, Tamas Revesz, Andrew J Lees

MOVEMENT DISORDERS | WILEY | Published : 2010

Grants

Funding Acknowledgements

This study was supported by the NIHR UCLH/UCL Comprehensive Biomedical Research Centre. SSOS, AJL, and JH are supported by the Reta Lila Weston Institute for Neurological Studies. JH, TR, and ZA are supported by the Sarah Matheson Trust for Multiple System Atrophy. JH and TR are supported by the Alzheimer's Research Trust, the Progressive Supranuclear Palsy (Europe) Association, and Brain Net Europe.Sean O'Sullivan: Has received honoraria from Britannia Pharmaceuticals. Employment: University College London. All other FD categories: None: Atbin Djamshidian: Employment: University College London. All other FD categories: None: Zeshan Ahmed: Employment: University College London. All other FD categories: None; Andrew Evans has served on advisory hoards and received honoraria from Boehringer Ingelheim, and Novartis. He has no other financial disclosures; Andrew Lawrence: Grants: UK Medical Research Council: UK Parkinson's Disease Society: Wales Institute of Cognitive Neuroscience. Employment: Cardiff University. All other categories: None: Janice Holton: Employment: University College London. All other FD categories: None; Minas Revesz: Employment: University College London. All other FD categories: None: Andrew Lees: advisory boards-Genus. Novartis. Teva, Medo, Boehringer Ingleheim, GSK, Ipsen, Lundbeck. Grants: PSP association, Reta Lila Weston Trust. All other categories: None.